BRAF and metastatic neoplasm: The authors concluded that there is currently insufficient evidence to definitively state that KRAS wild-type/BRAF-mutated metastatic tumors respond differently to anti-EGFR therapy compared with KRAS wild-type/BRAF wild-type tumors [43].